Islet transplantation in type 1 diabetic patients

F. Bertuzzi, A. Secchi, V. Di Carlo

Research output: Contribution to journalArticle

Abstract

Islet transplantation has been shown to improve overall glucose homeostasis and retard the progression of complications in type I diabetic patients. Also the percentage of recipients achieving complete insulin independence has progressively increased over recent years. An unsolved problem is whether the short-term graft function is secondary to progressive islet exhaustion or to recurrent autoimmunity despite the immunosuppressive therapy. The indications for this procedure remain limited to selected type I diabetic patients. The risks of the immunosuppressive therapy are only proposed to type I diabetic recipients with uncontrolled disease, despite all efforts of the diabetologist and the patient (brittle diabetes), or with a poor quality of life due to unawareness hypoglycemia or severe chronic and progressive complications.

Original languageEnglish
Pages (from-to)603-604
Number of pages2
JournalTransplantation Proceedings
Volume36
Issue number3
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Islets of Langerhans Transplantation
Immunosuppressive Agents
Autoimmunity
Hypoglycemia
Homeostasis
Quality of Life
Insulin
Transplants
Glucose
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Islet transplantation in type 1 diabetic patients. / Bertuzzi, F.; Secchi, A.; Di Carlo, V.

In: Transplantation Proceedings, Vol. 36, No. 3, 04.2004, p. 603-604.

Research output: Contribution to journalArticle

Bertuzzi, F. ; Secchi, A. ; Di Carlo, V. / Islet transplantation in type 1 diabetic patients. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 3. pp. 603-604.
@article{65f417d1839a4715b2f1c24e5ca1464b,
title = "Islet transplantation in type 1 diabetic patients",
abstract = "Islet transplantation has been shown to improve overall glucose homeostasis and retard the progression of complications in type I diabetic patients. Also the percentage of recipients achieving complete insulin independence has progressively increased over recent years. An unsolved problem is whether the short-term graft function is secondary to progressive islet exhaustion or to recurrent autoimmunity despite the immunosuppressive therapy. The indications for this procedure remain limited to selected type I diabetic patients. The risks of the immunosuppressive therapy are only proposed to type I diabetic recipients with uncontrolled disease, despite all efforts of the diabetologist and the patient (brittle diabetes), or with a poor quality of life due to unawareness hypoglycemia or severe chronic and progressive complications.",
author = "F. Bertuzzi and A. Secchi and {Di Carlo}, V.",
year = "2004",
month = "4",
doi = "10.1016/j.transproceed.2004.02.046",
language = "English",
volume = "36",
pages = "603--604",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Islet transplantation in type 1 diabetic patients

AU - Bertuzzi, F.

AU - Secchi, A.

AU - Di Carlo, V.

PY - 2004/4

Y1 - 2004/4

N2 - Islet transplantation has been shown to improve overall glucose homeostasis and retard the progression of complications in type I diabetic patients. Also the percentage of recipients achieving complete insulin independence has progressively increased over recent years. An unsolved problem is whether the short-term graft function is secondary to progressive islet exhaustion or to recurrent autoimmunity despite the immunosuppressive therapy. The indications for this procedure remain limited to selected type I diabetic patients. The risks of the immunosuppressive therapy are only proposed to type I diabetic recipients with uncontrolled disease, despite all efforts of the diabetologist and the patient (brittle diabetes), or with a poor quality of life due to unawareness hypoglycemia or severe chronic and progressive complications.

AB - Islet transplantation has been shown to improve overall glucose homeostasis and retard the progression of complications in type I diabetic patients. Also the percentage of recipients achieving complete insulin independence has progressively increased over recent years. An unsolved problem is whether the short-term graft function is secondary to progressive islet exhaustion or to recurrent autoimmunity despite the immunosuppressive therapy. The indications for this procedure remain limited to selected type I diabetic patients. The risks of the immunosuppressive therapy are only proposed to type I diabetic recipients with uncontrolled disease, despite all efforts of the diabetologist and the patient (brittle diabetes), or with a poor quality of life due to unawareness hypoglycemia or severe chronic and progressive complications.

UR - http://www.scopus.com/inward/record.url?scp=2042474781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042474781&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.02.046

DO - 10.1016/j.transproceed.2004.02.046

M3 - Article

C2 - 15110607

AN - SCOPUS:2042474781

VL - 36

SP - 603

EP - 604

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -